Johnson & Johnson (J&J), of New Brunswick, N.J., soared in its second quarter, with pharmaceuticals leading the way. While pharma took top billing, devices beat what had been forecast, with worldwide sales of $6.49 billion. That figure came above the $6.43 billion consensus, as Cowen's Joshua Jennings noted. Read More
Getting on top of the persistent HIV epidemic requires getting ahead of new cases, but only about 7% of at-risk patients have been advised of a prophylactic drug regime approved by the FDA seven years ago. Two new studies appearing in The Lancet HIV suggest that an algorithm that uses electronic health record (EHR) data can help physicians identify their at-risk patients who are good candidates for pre-exposure prophylaxis (PrEP), thus improving the odds that modern medicine might finally put an end to the scourge of acquired immunodeficiency syndrome. Read More
